Intact Vascular has announced the first commercial use of its Tack Endovascular System (4F) in multiple sites across the United States.
Notably the first Food and Drug Administration (FDA)-approved vascular implant for below-the-knee (BTK), post-angioplasty dissection repair, Tack implants are designed to optimize balloon angioplasty outcomes in the challenging critical limb ischemia (CLI) patient population.
“Effectively treating the small arteries affected in CLI has always been challenging. Over the years, various technologies have attempted to address this unique vasculature, but failed to provide an effective solution,” commented John Rundback, vascular and interventional radiologist and partner at the American Endovascular & Amputation Prevention Services in Clifton, New Jersey, one of the initial implanting sites. “Finally, I have an option that safely and effectively delivers better results below the knee for my CLI patients, and I am thrilled to incorporate this novel peripheral vascular implant into my treatment algorithm going forward.”
Regulatory approval was based on data from Intact Vascular’s Tack optimized balloon angioplasty II BTK (TOBA II BTK) clinical trial, which met all primary endpoints with 100% acute dissection resolution. The TOBA II BTK results were presented at the 2019 VIVA conference and demonstrated 95.7% K-M amputation-free survival, 87.3% K-M target lesion patency with significant improvement in toe-brachial index (TBI) and 92.0% K-M freedom from clinically driven reintervention at six months.
“As a company, Intact Vascular has sponsored multiple large-scale, prospective studies that have generated a solid and robust body of clinical evidence to support post-angioplasty dissection repair with the Tack Endovascular System,” noted S. Jay Mathews, interventional cardiologist and endovascular specialist at Bradenton Cardiology Center in Bradenton, Florida, another initial implanting site. “I am confident this game-changing technology will elevate the standard of care when performing endovascular procedures.”
“I would like to acknowledge our TOBA II BTK trial investigators for their collaboration and efforts to reach this important milestone,” commented Howard Rosen, vice president of marketing and business development for Intact Vascular. “There has been a long-standing and significant unmet need for a technology that addresses BTK disease. We are thrilled to provide the first FDA-approved peripheral vascular implant offering endovascular operators a novel tool that safely and effectively addresses this challenging condition and improves outcomes for their patients.”